Article Publication Announcement Signal Transduction and Targeted Therapy (www.nature.com/sigtrans)Astrocytic monoamine oxidase B (MAOB)–gamma-aminobutyric acid (GABA) axis as a molecular brake on repair following spinal cord injuryHye Yeong Lee, Jung Moo Lee, Hye-Lan Lee, Jiyeon Park, Heeyoung An, Eun Kyung Park, Sae Yeon Hwang, Sol lip Yoon, Gwang Yong Hwang, Keung Nyun Kim, Min-Ho Nam, Seung Eun Lee, Hyunji Kang, Joungha Won, Bo Ko Jang, Elijah Hwejin Lee, SunYeong Choi, Mingu Gordon Park, Sang Wook Kim, Ki Duk Park, SeungHwan Lee, C. Justin Lee & Yoon Ha DOI: 10.1038/s41392-025-02398-2

 On behalf of NeuroBiogen, we would like to inform you the about the Synergy Innovation Stock InquiriesImmediately after the distribution and release of press releases related to Tisolagiline's technology transfer, the stock price of its parent company, Synergy Innovation, has fluctuated, and shareholders are inquiring a lot.Therefore, we are informing you as follows. For all inquiries related to the stock price of Synergy Innovation, please contact Synergy Innovation. Since NeuroBiogen is not a listed company, we cannot answer your inquiries.For information regarding the Tisolagiline technology transfer contract, please refer to the media articles linked to the press release page on our website.We are not responsible for the content of articles published by media companies other than those published on the press release page of our website.All related contracts, including the Tisolagiline technology transfer contract, are subject to legal CDA between the parties to the contract, so we cannot inform you other than the fact that we disclosed them in a press release. Thank you. 

 Neurobiogen Co., Ltd. is an unlisted company and has no obligation to disclose it.The disclosure data of the parent company Synergy Innovation Co., Ltd. is referred to the Synergy Innovation Co., Ltd. website.Thank you. 

Neurobiogen currently has no hiring plans.  Thank you.